Gregory Bailey
CEO at Juvenescence and chairman of Portage Biotech
Dr. Gregory Bailey is chairman of Portage Biotech, Inc. a publicly traded drug development company and was previously managing partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 15 years of experience in investment banking and has founded several companies.
Along with comprehensive experience in healthcare, finance and
medicine, Greg brings an extensive involvement in corporate governance.
He has co-founded and served on multiple public and private company
boards of directors, such as Palantir Group, Inc., Ascent Healthcare
Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB),
DuraMedic Inc., and MediqVentures Ltd.
Visit website: https://juvenescence.ltd/team/
See also: 
Juvenescence
- Developing therapies against different aging related diseases.
Details last updated 21-Nov-2019
Gregory Bailey is also referenced in the following:
Investing in the Future of Longevity – the Ketone Chapter
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment
Longevity Investors Conference 2023
27-Sep-2023 to 29-Sep-2023
Conference gathering longevity experts and investors at one place hosted by Marc P. Bernegger, Dr. Tobias Reichmuth and Daniel Koetser
Longevity Leaders World Congress 2021
04-May-2021 to 07-May-2021
The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).
Longevity Leaders World Congress 2022
26-Feb-2022 to 27-Feb-2022
Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)
Gregory Bailey News
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeed
Read more...Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd
Juvenescence - 11-Jun-2020
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration
Read more...Today's 50 year-olds may live another 100 years
Forbes - 26-Aug-2019
Good summary of some major investments in life extension companies
Read more...FoxBio is developing small molecule drugs to target ageing diseases
Business Wire - 12-Jul-2018
Antoxerene partners with Juvenescence to discover drugs that clear senescent cells
Read more...UK biotech company focused on developing anti-ageing therapies
PMLiVE - 12-Jun-2018
LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs
Read more...British billionaire gambles on an anti-aging upstart
Endpoints News - 26-Jul-2017
We are at an inflection point for the treatment of aging. We can generate molecules with specifi...
Read more...
